Immuseven (Human Coagulation Factor Vii)

Immuseven is used to replace deficient factor VII activity in the extrinsic coagulation pathway for several bleeding disorders.

• Congenital factor VII deficiency: restores clotting ability to control spontaneous and trauma‑related bleeding.
• Hemophilia A or B with inhibitors: provides hemostasis during bleeding episodes when standard factor replacement is ineffective.
• Acquired hemophilia or severe surgical bleeding: achieves rapid clot formation to limit blood loss.
• Severe trauma in patients with coagulopathy: supplies immediate factor VII activity to support emergency hemostasis.

• Immuseven supplies exogenous human coagulation factor VII, which binds to tissue factor exposed at vascular injury sites. This complex activates factor X to Xa, initiating the extrinsic coagulation cascade and generating thrombin. The resulting fibrin clot stabilizes the hemorrhage, providing rapid hemostasis in patients lacking functional endogenous factor VII. The activity is dose‑dependent and enhances clot formation without requiring the intrinsic pathway.

Administration of Immuseven may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Fever: mild temperature elevation occurring shortly after infusion.
• Headache: transient cranial discomfort reported by some patients.
• Nausea: occasional gastrointestinal upset following administration.
• Injection site reactions: redness, swelling, or discomfort at the infusion site.

Serious or Rare Side Effects

• Thromboembolic events: formation of clots in veins or arteries, potentially leading to stroke or pulmonary embolism.
• Hypotension: sudden drop in blood pressure during or after infusion.
• Allergic reactions: anaphylaxis, urticaria, or severe skin eruptions requiring immediate medical attention.

Prior to using Immuseven, clinicians should evaluate patient history and monitor for specific risks.

• Thrombotic risk assessment: evaluate for prior clotting disorders or cardiovascular disease.
• Inhibitor screening: test for antibodies that may neutralize factor VII activity.
• Specialist supervision: administer only under the guidance of a hematology or coagulation expert.
• Hypersensitivity check: avoid use in patients with known allergy to recombinant factor VII products.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immuseven can interact with other medications that affect hemostasis, requiring careful management.

Major Interactions (Avoid)

• Concomitant use with other clotting factor concentrates: may increase risk of thrombotic complications.
• High‑dose estrogen therapy: additive pro‑coagulant effect can precipitate clot formation.
• Antifibrinolytic agents (e.g., tranexamic acid) combined with high doses: heightened thrombosis potential.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, heparin, direct oral anticoagulants): may diminish the hemostatic effect of Immuseven.
• Antiplatelet drugs (aspirin, clopidogrel): may require dose adjustment and close monitoring of bleeding parameters.